Skip to main content
Erschienen in: Journal of Gastrointestinal Cancer 3/2018

28.05.2018 | Editorial

Oesophageal Squamous Dysplasia

verfasst von: Michael Auld, Havish Srinath, Eshwarshanker Jeyarajan

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Excerpt

Squamous cell carcinoma (SCC) of the oesophagus is the most common neoplasia of the oesophagus worldwide [1]. In Australia, the incidence of oesophageal SCC is approximately 1 in 100,000 with males having a higher predilection [2]. The diagnosis is predominantly through endoscopic examination of the oesophagus. The overall incidence of oesophageal SCC has been trending downward over the last several decades [3, 4]. Western countries, in particular, have lower rates with some South African and Middle Eastern countries experiencing rates exceeding 100 in 100,000 [3]. Males are diagnosed with SCC in a ratio upwards of eight to one [4]. It represents a significant disease burden, associated with substantial morbidity, quality of life and a poor prognosis. Oesophageal cancer is graded by the TNM system which divides the carcinoma based on the depth of invasion through mucosa, submucosa and into adjacent structures [5]. …
Literatur
1.
Zurück zum Zitat Evans J, Early D, Chandraskhara V, et al. The role of endoscopy in the assessment and treatment of oesophageal cancer. Gastrointest Endosc. 2013;77:328–34.CrossRefPubMed Evans J, Early D, Chandraskhara V, et al. The role of endoscopy in the assessment and treatment of oesophageal cancer. Gastrointest Endosc. 2013;77:328–34.CrossRefPubMed
2.
Zurück zum Zitat Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 2015;64:381–7.CrossRefPubMed Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 2015;64:381–7.CrossRefPubMed
3.
Zurück zum Zitat Messman H. Squamous cell cancer of the oesophagus. Best Pract Res Clin Gastroenterol. 2001;15:249–65.CrossRef Messman H. Squamous cell cancer of the oesophagus. Best Pract Res Clin Gastroenterol. 2001;15:249–65.CrossRef
4.
Zurück zum Zitat Yong E, Han XP, Watson D, et al. Outcome following surgery for squamous cell carcinoma of the oesophagus. ANZJSurg. 2009;79:724–8. Yong E, Han XP, Watson D, et al. Outcome following surgery for squamous cell carcinoma of the oesophagus. ANZJSurg. 2009;79:724–8.
5.
Zurück zum Zitat Rice T, Patil D, Blackstone E. 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann Cardiothoracic Surg. 2017;6:119–30.CrossRef Rice T, Patil D, Blackstone E. 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann Cardiothoracic Surg. 2017;6:119–30.CrossRef
6.
Zurück zum Zitat Chen S, Zhou K, Yang L, Ding G, Li H. Racial differences in esophageal squamous cell carcinoma: incidence and molecular features. Biomed Res Int. 2017;2017:1–9. Chen S, Zhou K, Yang L, Ding G, Li H. Racial differences in esophageal squamous cell carcinoma: incidence and molecular features. Biomed Res Int. 2017;2017:1–9.
7.
Zurück zum Zitat Deng J, Chen H, Zhou D, et al. Comparative genomic analysis of esophageal squamous cell carcinoma between Asian and Caucasian patient populations. Nat Commun. 2017;8:1–9.CrossRef Deng J, Chen H, Zhou D, et al. Comparative genomic analysis of esophageal squamous cell carcinoma between Asian and Caucasian patient populations. Nat Commun. 2017;8:1–9.CrossRef
9.
Zurück zum Zitat Alsobahi F, Collis S, Hunter K. The role of Fanconi Anaemia pathway in sporadic non-FA associated head and neck squamous cell carcinoma. Eur J Cancer. 2016;61:S35.CrossRef Alsobahi F, Collis S, Hunter K. The role of Fanconi Anaemia pathway in sporadic non-FA associated head and neck squamous cell carcinoma. Eur J Cancer. 2016;61:S35.CrossRef
10.
Zurück zum Zitat Tipples K, Raouf S. Treatment of oesophageal squamous cell carcinoma in a patient with Fanconi anaemia. Clin Oncol. 2008;3:383–4.CrossRef Tipples K, Raouf S. Treatment of oesophageal squamous cell carcinoma in a patient with Fanconi anaemia. Clin Oncol. 2008;3:383–4.CrossRef
11.
Zurück zum Zitat Bass A, Laird P, Shmulevich I. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;12:169–75. Bass A, Laird P, Shmulevich I. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;12:169–75.
12.
Zurück zum Zitat Petrick J, Wyss A, Butler A. Prevalence of human papillomavirus among oesophageal squamous cell carcinoma cases: systematic review and meta-analysis. Br J Cancer. 2014;110:2369–77.CrossRefPubMedPubMedCentral Petrick J, Wyss A, Butler A. Prevalence of human papillomavirus among oesophageal squamous cell carcinoma cases: systematic review and meta-analysis. Br J Cancer. 2014;110:2369–77.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Siewert J, Ott K. Are squamous and adenocarcinomas of the oesophagus the same disease? Semin Radiat Oncol. 2007;17:38–44.CrossRefPubMed Siewert J, Ott K. Are squamous and adenocarcinomas of the oesophagus the same disease? Semin Radiat Oncol. 2007;17:38–44.CrossRefPubMed
14.
Zurück zum Zitat Liu X, Zhang M, Ying S, Zhang C, Lin R, Zheng J, et al. Genetic alterations in esophageal tissues from squamous dysplasia to carcinoma. Gastroenterology. 2017;153:166–77.CrossRefPubMed Liu X, Zhang M, Ying S, Zhang C, Lin R, Zheng J, et al. Genetic alterations in esophageal tissues from squamous dysplasia to carcinoma. Gastroenterology. 2017;153:166–77.CrossRefPubMed
15.
Zurück zum Zitat Smyth E, Lagergren J, Fitzgerald R, Lordick F, Shah M, Lagergren P, et al. Oesophageal cancer. Nature. 2017;3:1–21. Smyth E, Lagergren J, Fitzgerald R, Lordick F, Shah M, Lagergren P, et al. Oesophageal cancer. Nature. 2017;3:1–21.
16.
Zurück zum Zitat Siewert J, Stein H, Feith M, et al. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western World. Ann Surg. 2001;234:360–7.CrossRefPubMedPubMedCentral Siewert J, Stein H, Feith M, et al. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western World. Ann Surg. 2001;234:360–7.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Haidry R, Butt M, Dunn J, et al. Radiofrequency ablation for early oesophageal squamous neoplasia: outcomes form United Kingdom registry. World J Gastroenterol. 2013;19:6011–9.CrossRefPubMedPubMedCentral Haidry R, Butt M, Dunn J, et al. Radiofrequency ablation for early oesophageal squamous neoplasia: outcomes form United Kingdom registry. World J Gastroenterol. 2013;19:6011–9.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Mannath J, Ragunath K. Endoscopic mucosal resection: who and how? Ther Adv Gastroenterol. 2010;4:275–82.CrossRef Mannath J, Ragunath K. Endoscopic mucosal resection: who and how? Ther Adv Gastroenterol. 2010;4:275–82.CrossRef
19.
Zurück zum Zitat Dutton S, Ferry D, Blazeby J, et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncol. 2014;15:894–904.CrossRefPubMed Dutton S, Ferry D, Blazeby J, et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncol. 2014;15:894–904.CrossRefPubMed
20.
Zurück zum Zitat Song L, Wilson B. Endoscopic detection of early upper GI cancers. Best Pract Res Clin Gastroenterol. 2005;19:833–56.CrossRef Song L, Wilson B. Endoscopic detection of early upper GI cancers. Best Pract Res Clin Gastroenterol. 2005;19:833–56.CrossRef
21.
Zurück zum Zitat Lao-Sirieix P, Fitzgerald R. Screening for oesophageal cancer. Nature. 2012;9:278–86. Lao-Sirieix P, Fitzgerald R. Screening for oesophageal cancer. Nature. 2012;9:278–86.
22.
Zurück zum Zitat Evans J, Early D, Fukami N. The role of endoscopy in Barretts oesophagus and other premalignant conditions of the esophagus. Gastrointest Endosc. 2012;76:1087–94.CrossRefPubMed Evans J, Early D, Fukami N. The role of endoscopy in Barretts oesophagus and other premalignant conditions of the esophagus. Gastrointest Endosc. 2012;76:1087–94.CrossRefPubMed
23.
Zurück zum Zitat Walker M, Harris A, Edwards G, Talley N. A GP primer for understanding upper gastrointestinal tract biopsy reports. AFP. 2015;44:706–11.PubMed Walker M, Harris A, Edwards G, Talley N. A GP primer for understanding upper gastrointestinal tract biopsy reports. AFP. 2015;44:706–11.PubMed
24.
Zurück zum Zitat Doi T, Piha-Paul SA, Jalal SI, Mai-Dang H, Saraf S, Koshiji M, et al. Updated results for the advanced esophageal carcinoma cohort of the phase Ib KEYNOTE-028 study of pembrolizumab (MK-3475). J Clin Oncol. 2016;34(4_suppl):7-7. Doi T, Piha-Paul SA, Jalal SI, Mai-Dang H, Saraf S, Koshiji M, et al. Updated results for the advanced esophageal carcinoma cohort of the phase Ib KEYNOTE-028 study of pembrolizumab (MK-3475). J Clin Oncol. 2016;34(4_suppl):7-7.
25.
Zurück zum Zitat Kang Y, Satoh T, Ryu M, et al. Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): a double-blinded, randomized, phase III trial. J Clin Oncol. 2017;35:2–2.CrossRef Kang Y, Satoh T, Ryu M, et al. Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): a double-blinded, randomized, phase III trial. J Clin Oncol. 2017;35:2–2.CrossRef
Metadaten
Titel
Oesophageal Squamous Dysplasia
verfasst von
Michael Auld
Havish Srinath
Eshwarshanker Jeyarajan
Publikationsdatum
28.05.2018
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 3/2018
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-018-0122-3

Weitere Artikel der Ausgabe 3/2018

Journal of Gastrointestinal Cancer 3/2018 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.